# Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Source: https://onco.cc/trials/nct04274426/  
OnCo record `nct04274426` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Carboplatin, Doxorubicin, Pegylated liposomal doxorubicin, Gemcitabine and Mirvetuximab soravtansine in ovarian cancer, run by AGO Research GmbH, active and no longer recruiting.

## Summary

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT04274426 by AGO Research GmbH, with 136 participants enrolled, started 2021-10-13 and due to reach its primary completion in 2025-12-03. Interventions recorded: Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel and Mirvetuximab Soravtansine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04274426
- Phase: 2
- Setting: A Randomized Phase II Trial of Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer Eligible for Platinum-based Chemotherapy. Supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967
- Sponsor: AGO Research GmbH
- Enrolled: 136

## Sources

- ClinicalTrials.gov NCT04274426: https://clinicaltrials.gov/study/NCT04274426

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/)

---
JSON: https://onco.cc/api/v1/entities/nct04274426.json